Mel JuSoHomo sapiens (Human)Cancer cell line
Also known as: JuSo, MELJUSO, MelJuSo, Mel Juso, Mel-Juso, MEL-JUSO, MEL-Juso
Quick Overview
Human melanoma cell line with known mutations in NRAS and BRAF.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1403 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Skin[UBERON:UBERON_0002097] |
Donor Information
| Age | 58 |
|---|---|
| Age Category | Adult |
| Sex | Female |
Disease Information
| Disease | Cutaneous melanoma |
|---|---|
| Lineage | Skin |
| Subtype | Cutaneous Melanoma |
| OncoTree Code | SKCM |
DepMap Information
| Source Type | DSMZ |
|---|---|
| Source ID | ACH-000881_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | NRAS | p.Gln61Leu (c.182A>T) | Unspecified | - | PubMed=26214590 |
| MutationSimple | HRAS | p.Gly13Asp (c.38G>A) | Unspecified | - | PubMed=24662767 |
| Gene deletion | CDKN2B | - | Homozygous | - | PubMed=35933914 |
| Gene deletion | CDKN2A | - | Homozygous | Possible | PubMed=26870271 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
HER3 is a determinant for poor prognosis in melanoma.";
Wild P.J., Hutterer M., Meyer S., Dummer R., Moch H., Ullrich A.
Clin. Cancer Res. 14:5188-5197(2008).
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
Tsao H., Goel V., Wu H., Yang G., Haluska F.G.
J. Invest. Dermatol. 122:337-341(2004).
Immunocytochemical analysis of cell lines derived from solid tumors.
Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.
J. Histochem. Cytochem. 49:1369-1378(2001).
Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
Tsao H., Zhang X., Fowlkes K., Haluska F.G.
Cancer Res. 60:1800-1804(2000).
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Fountain J.W.
Genes Chromosomes Cancer 22:157-163(1998).
Surface antigens of human melanoma cells defined by monoclonal antibodies. I. Biochemical characterization of two antigens found on cell lines and fresh tumors of diverse tissue origin.
Johnson J.P., Demmer-Dieckmann M., Meo T., Hadam M.R., Riethmuller G.
Eur. J. Immunol. 11:825-831(1981).